Literature DB >> 15188333

Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus.

Jennifer B Soep1, Michele Mietus-Snyder, Mary J Malloy, Joseph L Witztum, Emily von Scheven.   

Abstract

OBJECTIVE: To characterize atherosclerotic risk factors and endothelial function in pediatric-onset systemic lupus erythematosus (SLE).
METHODS: Lipoproteins, oxidized state, and autoantibodies to oxidized low-density lipoprotein (Ox-LDL) were assessed. Endothelial function was evaluated using brachial artery reactivity.
RESULTS: Thirty-three SLE patients and 30 controls were studied. SLE subjects had significantly decreased mean high-density lipoprotein (HDL) cholesterol (41 mg/dl versus 51 mg/dl; P = 0.002) and apolipoprotein A-I (97 mg/dl versus 199 mg/dl; P = 0.0004). There was no difference between groups in markers of oxidized state (including nitric oxide metabolites, isoprostanes, and Ox-LDL) or in endothelial function. However, SLE subjects had increased median anti-Ox-LDL IgG (2,480 relative light units [RLU] versus 1,567 RLU; P = 0.0007) and IgG immune complexes with LDL (4,222 RLU versus 2,868 RLU; P = 0.002).
CONCLUSION: Pediatric SLE patients had significantly decreased levels of HDL cholesterol and apolipoprotein A-I and elevated titers of autoantibodies to Ox-LDL. Despite these atherosclerotic risk factors, SLE patients had normal measures of oxidized state and endothelial function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188333     DOI: 10.1002/art.20392

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 2.  Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Authors:  Mohammed M Al Gadban; Mohamed M Alwan; Kent J Smith; Samar M Hammad
Journal:  Clin Immunol       Date:  2015-01-28       Impact factor: 3.969

3.  Ambulatory blood pressure and subclinical cardiovascular disease in patients with juvenile-onset systemic lupus erythematosus.

Authors:  Nur Canpolat; Ozgur Kasapcopur; Salim Caliskan; Selman Gokalp; Meltem Bor; Mehmet Tasdemir; Lale Sever; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2012-10-10       Impact factor: 3.714

4.  Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Authors:  L E Schanberg; C Sandborg; H X Barnhart; S P Ardoin; E Yow; G W Evans; K L Mieszkalski; N T Ilowite; A Eberhard; L F Imundo; Y Kimura; E von Scheven; E Silverman; S L Bowyer; M Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L Jung; J B Soep; A M Reed; J Provenzale; S D Thompson
Journal:  Arthritis Rheum       Date:  2012-01

5.  Dyslipidemia in patients with systemic lupus erythematosus: Association with disease activity and B-type natriuretic peptide levels.

Authors:  Jiangshui Yuan; L I Li; Zhaoyan Wang; Weiqing Song; Zongliang Zhang
Journal:  Biomed Rep       Date:  2015-11-18

6.  Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Authors:  S P Ardoin; L E Schanberg; C Sandborg; E Yow; H X Barnhart; K l Mieszkalski; N T Ilowite; E von Scheven; A Eberhard; D M Levy; Y Kimura; E Silverman; S L Bowyer; L Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L K Jung; L Imundo; J B Soep; A M Reed
Journal:  Lupus       Date:  2010-10       Impact factor: 2.911

7.  Levels of F2 isoprostane in Behcet's disease: Correlation with cardiometabolic risk factors.

Authors:  Gul Sagun; Aytekin Oguz; Banu Mesci; Banu Isbilen; Mukaddes Kavala; Havva Keskin; Mumtaz Takir; Sibel Zehra Aydin
Journal:  Redox Rep       Date:  2015-04-13       Impact factor: 4.412

Review 8.  Dyslipidemia in systemic lupus erythematosus.

Authors:  Melinda Zsuzsanna Szabó; Peter Szodoray; Emese Kiss
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

9.  Lipid profile among girls with systemic lupus erythematosus.

Authors:  Daniele Machado; Roseli O S Sarni; Thaís T O Abad; Simone G L Silva; Eugênia J B Khazaal; Sonia Hix; Milena S G Correia; Fabíola I Suano-Souza; Claudio A Len; Maria Teresa R A Terreri
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

10.  Metabolic abnormalities and cardiovascular risk factors in children with myositis.

Authors:  Kathleen Coyle; Kristina I Rother; Martina Weise; Alaa Ahmed; Frederick W Miller; Lisa G Rider
Journal:  J Pediatr       Date:  2009-07-29       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.